ACM
BLUE

Accent Capital Management’s bluebird bio BLUE Stock Holding History

Accent Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$244 – 399
2025
Q1 		$244 Hold
50
– – ﹤0.01% 319
2024
Q4 		$417 Hold
50
– – ﹤0.01% 185
2024
Q3 		$520 Sell
50
-35
-41% -$582 ﹤0.01% 205
2024
Q2 		$1.67K Hold
85
– – ﹤0.01% 174
2024
Q1 		$2.18K Sell
85
-83
-49% -$2.13K ﹤0.01% 159
2023
Q4 		$4.62K Buy
+168
New +$10.2K ﹤0.01% 192

Other funds holding BLUE

Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Accent Capital Management's BLUE Position: Q2 2025 in Review

Accent Capital Management sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 50 shares — an estimated $244 sold.

Accent Capital Management first reported a position in BLUE in Q4 2023 and held it in 6 quarters. The position peaked at $4.62K in Q4 2023. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

  • Accent Capital Management reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
  • Accent Capital Management sold 50 bluebird bio shares in Q2 2025, an estimated $244.
  • Accent Capital Management first reported a position in bluebird bio in Q4 2023 and held it in 6 quarters.
  • Accent Capital Management's bluebird bio position peaked at $4.62K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on Accent Capital Management's 13F filing for Q2 2025, filed 7 Aug 2025.